Association of genetically enhanced lipoprotein lipase–mediated lipolysis and low-density lipoprotein cholesterol–lowering alleles with risk of coronary disease and type 2 diabetes

<strong>Importance</strong> Pharmacological enhancers of lipoprotein lipase (LPL) are in preclinical or early clinical development for cardiovascular prevention. Studying whether these agents will reduce cardiovascular events or diabetes risk when added to existing lipid-lowering drugs...

Πλήρης περιγραφή

Λεπτομέρειες βιβλιογραφικής εγγραφής
Κύριοι συγγραφείς: Lotta, LA, Stewart, ID, Sharp, SJ, Day, FR, Burgess, S, Luan, J, Bowker, N, Cai, L, Li, C, Wittemans, LBL, Kerrison, ND, Khaw, K-T, McCarthy, MI, O'Rahilly, S, Scott, RA, Savage, DB, Perry, JRB, Langenberg, C, Wareham, NJ
Μορφή: Journal article
Έκδοση: American Medical Association 2018

Παρόμοια τεκμήρια